Konishi Takaaki, Kumamaru Hiraku, Niikura Naoki, Sagara Yasuaki, Miyashita Minoru, Iwamoto Takayuki, Sanuki Naoko, Tanakura Kenta, Nagahashi Masayuki, Yoshida Masayuki, Kawashima Masahiro, Kinoshita Takayuki, Sasada Shinsuke, Kinukawa Naoko, Saji Shigehira, Ishida Takanori, Taira Naruto
Department of Breast and Endocrine Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Healthcare Quality Assessment, University of Tokyo, 7‑3‑1 Hongo, Bunkyo‑Ku, Tokyo, 113‑8655, Japan.
Breast Cancer. 2025 Apr 21. doi: 10.1007/s12282-025-01698-3.
The Japanese Breast Cancer Society initiated the breast cancer registry in 1975 and migrated the registry to the National Clinical Database-Breast Cancer Registry (NCD-BCR) in 2012. This annual report presents 2021 data on the NCD-BCR. We analyzed data from 98,540 breast cancer (BC) cases registered in 2021. In 2021, 99.4% of BC cases were females with a median age of 61. Most (57.5%) were diagnosed at early stages (Stage 0 or I). Breast-conserving surgery was performed in 42.8% of cases. Sentinel lymph node biopsy was performed in 67.8%, followed by radiotherapy in 71.0% of those post-conserving surgery. Regarding postoperative systemic therapy, 63.1% received endocrine therapy, 28.2% received chemotherapy, and 14.9% received molecular-targeted therapy. ER positivity was observed in 75.2%, HER2 in 13.6%, and Ki67 ≥30% in 29.1% of cases. The median age of premenopausal cases was 46 (interquartile range, 42-49) years and the median BMI was 21.5 (19.7-24.2) kg/m whereas the median age of postmenopausal cases was 69 (61-76) years and the median BMI was 23.0 (20.6-25.9) kg/m. In premenopausal cases, cases with normal BMI were more likely to be found at checkups without subjective symptoms and in the early stage than those with high BMI. The tendency of ER, PgR, HER2, and Ki67 status on BMI differed by menopause status; premenopausal cases with a lower BMI showed higher proportions of ER- and PgR-positive cancer and lower proportions of cancer with high Ki67. These nationwide descriptive statistics would help clinical explanation and further research on breast cancer.
日本乳腺癌协会于1975年启动了乳腺癌登记工作，并于2012年将该登记系统迁移至国家临床数据库 - 乳腺癌登记处（NCD - BCR）。本年报展示了NCD - BCR的2021年数据。我们分析了2021年登记的98,540例乳腺癌（BC）病例的数据。2021年，99.4%的BC病例为女性，中位年龄为61岁。大多数（57.5%）在早期阶段（0期或I期）被诊断出来。42.8%的病例接受了保乳手术。67.8%的病例进行了前哨淋巴结活检，保乳手术后71.0%的病例接受了放疗。关于术后全身治疗，63.1%的患者接受了内分泌治疗，28.2%接受了化疗，14.9%接受了分子靶向治疗。75.2%的病例观察到雌激素受体（ER）阳性，13.6%的病例人表皮生长因子受体2（HER2）阳性，29.1%的病例Ki67≥30%。绝经前病例的中位年龄为46岁（四分位间距，42 - 49岁），中位体重指数（BMI）为21.5（19.7 - 24.2）kg/m²，而绝经后病例的中位年龄为69岁（61 - 76岁），中位BMI为23.0（20.6 - 25.9）kg/m²。在绝经前病例中，BMI正常的病例比BMI高的病例更有可能在无主观症状的体检中被发现且处于早期阶段。ER、孕激素受体（PgR）、HER2和Ki67状态在BMI上的趋势因绝经状态而异；BMI较低的绝经前病例中ER和PgR阳性癌症的比例较高，而Ki67高的癌症比例较低。这些全国性的描述性统计数据将有助于乳腺癌的临床解释和进一步研究。
